Arca
Skip to content
Tools
Tools

CD27: CD27 antigen

Costimulatory immune-checkpoint receptor expressed at the surface of T-cells, NK-cells and B-cells which binds to and is activated by its ligand CD70/CD27L expressed by B-cells.

  • Drugs that act on it: 1
  • Approved: 0
  • In phases 1 to 3: 1
  • Sponsors: 1

Who is on it, and how far along

Every drug ChEMBL records acting on CD27, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody 1

Approved0

    Phase 30

      Phase 21

      • Varlilumab

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        DrugFurthest stageSponsorModalityActionOpen trials
        VarlilumabPhase 2Celldex TherapeuticsAntibodyAgonistCD27 antigen agonist3

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 3 in all, from ClinicalTrials.gov.
        Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract CancerVarlilumabPhase 2Active, not recruitingNational Cancer Institute (NCI)Jun 28, 2021
        DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without VarlilumabVarlilumabPhase 2Active, not recruitingAnnick Desjardins, MDSep 28, 2018
        Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell LymphomasVarlilumabPhase 2Active, not recruitingNational Cancer Institute (NCI)Feb 1, 2017

        Diseases most associated with it

        Open Targets association score, 0 to 1; all associations
        • Lymphoproliferative syndrome 20.70
        • Autosomal recessive lymphoproliferative disease0.66
        • Lymphoproliferative syndrome0.62
        • Combined immunodeficiency0.57
        • Immunodeficiency disease0.43
        • Neurodegenerative disease0.38
        • Hereditary disease0.19
        • Autoinflammatory syndrome0.17
        • Neoplasm0.12

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3713333, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P26842, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.